The global market for Novel Drug Delivery Systems was valued at US$ 25130 million in the year 2024 and is projected to reach a revised size of US$ 28230 million by 2031, growing at a CAGR of 1.7% during the forecast period.
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein鈥揹rug Conjugates
Others
Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Drug Delivery Systems company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Novel Drug Delivery Systems 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Liposomes
1.2.3 PEGylated Proteins & Polypeptides
1.2.4 Polymer Nanoparticle
1.2.5 Protein鈥揹rug Conjugates
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Novel Drug Delivery Systems 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals & Clinic
1.3.3 Cancer Treatment Centers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel Drug Delivery Systems 麻豆原创 Perspective (2020-2031)
2.2 Global Novel Drug Delivery Systems Growth Trends by Region
2.2.1 Global Novel Drug Delivery Systems 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Novel Drug Delivery Systems Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Novel Drug Delivery Systems 麻豆原创 Dynamics
2.3.1 Novel Drug Delivery Systems Industry Trends
2.3.2 Novel Drug Delivery Systems 麻豆原创 Drivers
2.3.3 Novel Drug Delivery Systems 麻豆原创 Challenges
2.3.4 Novel Drug Delivery Systems 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel Drug Delivery Systems Players by Revenue
3.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2020-2025)
3.1.2 Global Novel Drug Delivery Systems Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Novel Drug Delivery Systems 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Novel Drug Delivery Systems Revenue
3.4 Global Novel Drug Delivery Systems 麻豆原创 Concentration Ratio
3.4.1 Global Novel Drug Delivery Systems 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Drug Delivery Systems Revenue in 2024
3.5 Global Key Players of Novel Drug Delivery Systems Head office and Area Served
3.6 Global Key Players of Novel Drug Delivery Systems, Product and Application
3.7 Global Key Players of Novel Drug Delivery Systems, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel Drug Delivery Systems Breakdown Data by Type
4.1 Global Novel Drug Delivery Systems Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Type (2026-2031)
5 Novel Drug Delivery Systems Breakdown Data by Application
5.1 Global Novel Drug Delivery Systems Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Novel Drug Delivery Systems 麻豆原创 Size (2020-2031)
6.2 North America Novel Drug Delivery Systems 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Novel Drug Delivery Systems 麻豆原创 Size by Country (2020-2025)
6.4 North America Novel Drug Delivery Systems 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel Drug Delivery Systems 麻豆原创 Size (2020-2031)
7.2 Europe Novel Drug Delivery Systems 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Novel Drug Delivery Systems 麻豆原创 Size by Country (2020-2025)
7.4 Europe Novel Drug Delivery Systems 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel Drug Delivery Systems 麻豆原创 Size (2020-2031)
9.2 Latin America Novel Drug Delivery Systems 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Novel Drug Delivery Systems 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Novel Drug Delivery Systems 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Novel Drug Delivery Systems Introduction
11.1.4 Amgen Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Novel Drug Delivery Systems Introduction
11.2.4 Teva Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Novel Drug Delivery Systems Introduction
11.3.4 Roche Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.3.5 Roche Recent Development
11.4 UCB (Union Chimique Belge)
11.4.1 UCB (Union Chimique Belge) Company Details
11.4.2 UCB (Union Chimique Belge) Business Overview
11.4.3 UCB (Union Chimique Belge) Novel Drug Delivery Systems Introduction
11.4.4 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.4.5 UCB (Union Chimique Belge) Recent Development
11.5 Celgene
11.5.1 Celgene Company Details
11.5.2 Celgene Business Overview
11.5.3 Celgene Novel Drug Delivery Systems Introduction
11.5.4 Celgene Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.5.5 Celgene Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Novel Drug Delivery Systems Introduction
11.6.4 Merck Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.6.5 Merck Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Details
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Novel Drug Delivery Systems Introduction
11.7.4 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.7.5 Gilead Sciences Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Novel Drug Delivery Systems Introduction
11.8.4 Sanofi Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.8.5 Sanofi Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Novel Drug Delivery Systems Introduction
11.9.4 Pfizer Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.9.5 Pfizer Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Novel Drug Delivery Systems Introduction
11.10.4 Takeda Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.10.5 Takeda Recent Development
11.11 Bausch&Lomb
11.11.1 Bausch&Lomb Company Details
11.11.2 Bausch&Lomb Business Overview
11.11.3 Bausch&Lomb Novel Drug Delivery Systems Introduction
11.11.4 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.11.5 Bausch&Lomb Recent Development
11.12 Samyang Biopharmaceuticals
11.12.1 Samyang Biopharmaceuticals Company Details
11.12.2 Samyang Biopharmaceuticals Business Overview
11.12.3 Samyang Biopharmaceuticals Novel Drug Delivery Systems Introduction
11.12.4 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.12.5 Samyang Biopharmaceuticals Recent Development
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Details
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Novel Drug Delivery Systems Introduction
11.13.4 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.13.5 Johnson & Johnson Recent Development
11.14 TOLMAR
11.14.1 TOLMAR Company Details
11.14.2 TOLMAR Business Overview
11.14.3 TOLMAR Novel Drug Delivery Systems Introduction
11.14.4 TOLMAR Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.14.5 TOLMAR Recent Development
11.15 Astellas
11.15.1 Astellas Company Details
11.15.2 Astellas Business Overview
11.15.3 Astellas Novel Drug Delivery Systems Introduction
11.15.4 Astellas Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.15.5 Astellas Recent Development
11.16 AMAG Pharmaceuticals
11.16.1 AMAG Pharmaceuticals Company Details
11.16.2 AMAG Pharmaceuticals Business Overview
11.16.3 AMAG Pharmaceuticals Novel Drug Delivery Systems Introduction
11.16.4 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.16.5 AMAG Pharmaceuticals Recent Development
11.17 AbbVie
11.17.1 AbbVie Company Details
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Novel Drug Delivery Systems Introduction
11.17.4 AbbVie Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.17.5 AbbVie Recent Development
11.18 Dr Reddy
11.18.1 Dr Reddy Company Details
11.18.2 Dr Reddy Business Overview
11.18.3 Dr Reddy Novel Drug Delivery Systems Introduction
11.18.4 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.18.5 Dr Reddy Recent Development
11.19 AstraZeneca
11.19.1 AstraZeneca Company Details
11.19.2 AstraZeneca Business Overview
11.19.3 AstraZeneca Novel Drug Delivery Systems Introduction
11.19.4 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.19.5 AstraZeneca Recent Development
11.20 Aspen
11.20.1 Aspen Company Details
11.20.2 Aspen Business Overview
11.20.3 Aspen Novel Drug Delivery Systems Introduction
11.20.4 Aspen Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.20.5 Aspen Recent Development
11.21 Acrotech Biopharma
11.21.1 Acrotech Biopharma Company Details
11.21.2 Acrotech Biopharma Business Overview
11.21.3 Acrotech Biopharma Novel Drug Delivery Systems Introduction
11.21.4 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.21.5 Acrotech Biopharma Recent Development
11.22 TWi Pharmaceuticals
11.22.1 TWi Pharmaceuticals Company Details
11.22.2 TWi Pharmaceuticals Business Overview
11.22.3 TWi Pharmaceuticals Novel Drug Delivery Systems Introduction
11.22.4 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
11.22.5 TWi Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
听
听
*If Applicable.
